VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 14, 2010) - Sirona Biochem Corp. (TSX VENTURE: SBM) (the "Company"), a biotechnology company specializing in carbohydrate-based molecules, including therapeutics for diabetes and obesity, cosmeceuticals and biological ingredients, announced today that it has appointed advertising executive Frank Palmer as Advisor. Mr. Palmer is currently Chairman and CEO of DDB Canada, one of Canada's leading advertising firms.
"Frank Palmer is a highly-acclaimed advertising and marketing leader and he brings to Sirona Biochem an impressive business background," said Mark Senner, President of Sirona Biochem. "Sirona Biochem is at a pivotal stage of developing new diabetes and obesity therapeutics and anti-aging cosmetic ingredients. We are pleased to be able to attract business leaders such as Frank Palmer as we advance our scientific technology and build partnerships," he added.
About Frank Palmer
Frank Palmer is Chairman and CEO of DDB Canada. From his humble beginnings in Vancouver, Mr. Palmer has created Canada's most creatively acclaimed marketing communications agency and in the process, has changed the face of Canadian advertising. In recognition of his outstanding contributions to the advertising industry, Mr. Palmer has been inducted into the Canadian Marketing Hall of Legends by the American Marketing Association and is a recipient of the Association of Canadian Advertisers' prestigious Gold Medal Award. But it's not only his abilities as an exceptional business leader that make Mr. Palmer unique. He is also a philanthropist at heart and a true believer in corporate social responsibility. Mr. Palmer is a Founder of the National Advertising Benevolent Society (NABS) in Canada, and has provided his expertise and influence to numerous industry and charitable organizations. Most recently, Mr. Palmer founded Palmer Encore Ventures with business partner and investment executive Michael Rogers. A graduate of the Vancouver School of Art (now Emily Carr University of Art and Design), Mr. Palmer still enjoys painting in his free time.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, anti-aging cosmetic ingredients and biological ingredients. Our proprietary chemistry expertise is being applied towards the development of these carbohydrate-based programs. Our aim is to improve the commercial value of carbohydrate-based molecules by improving their pharmaceutical qualities. In August 2010, Sirona Biochem announced it had signed a binding preliminary agreement to acquire France-based TFChem. For more information visit www.sironabiochem.com.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements.